Arduan2 ml

Arduan is a long-acting non-depolarizing (competitive) neuromuscular blocking agent used only in a monitored anesthesia or critical-care setting, always as an adjunct to general anesthesia given by, or under the direct supervision of, personnel trained in airway management and mechanical ventilation.

Established / approved uses

• As an adjunct to general anesthesia to facilitate endotracheal intubation.
• To provide skeletal muscle relaxation during surgical procedures of intermediate to long duration.
• To facilitate controlled mechanical ventilation in the operating room or intensive care unit when profound, sustained muscle relaxation is required.

Not appropriate for

• Rapid-sequence induction/intubation, because its onset of action is relatively slow compared with agents specifically chosen for that purpose.
• Use outside a setting with continuous airway and ventilatory support, since Arduan produces complete skeletal muscle paralysis, including the muscles of respiration.

Arduan must always be given together with adequate general anesthesia or sedation; it has no analgesic or sedative/amnestic effect of its own, and administering it to a patient who is not adequately anesthetized is a severe patient-safety hazard (the patient will be paralyzed but conscious and able to feel pain).

Each vial contains Pipecuronium Bromide as the active pharmaceutical ingredient, supplied as a sterile, lyophilized (freeze-dried) powder for reconstitution into a solution for intravenous injection. Available strengths and pack sizes vary by manufacturer; a mannitol base and pH-adjusting excipients are typically included to stabilize the lyophilized powder. The reconstituted solution contains no antimicrobial preservative and is intended for single-patient, in-hospital use only.

Arduan is a bisquaternary aminosteroid, long-acting, non-depolarizing skeletal muscle relaxant used exclusively in the hospital setting as an adjunct to general anesthesia. It belongs to the same structural class as pancuronium but was developed to have a more favorable cardiovascular profile, with minimal vagolytic (heart-rate-raising) and histamine-releasing activity at clinically used doses.

Arduan is administered only by the intravenous route by an anesthesiologist or other qualified practitioner trained in airway management, with equipment for tracheal intubation, mechanical ventilation, and oxygen administration immediately available. It is not a sedative, analgesic, or anesthetic, and it does not alter consciousness or pain perception.

Arduan belongs to the therapeutic class of neuromuscular blocking agents (skeletal muscle relaxants), non-depolarizing type, used as adjuncts to general anesthesia. Within this class it is further categorized as a long-acting aminosteroid non-depolarizing agent.

Mechanism of action

Pipecuronium Bromide acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor endplate of the neuromuscular junction. By competitively blocking acetylcholine from binding these receptors, it prevents depolarization of the muscle end-plate and the resulting muscle contraction, producing flaccid skeletal muscle paralysis. Because the block is competitive, it can be reversed by increasing the local concentration of acetylcholine, for example with an acetylcholinesterase inhibitor such as neostigmine.

Pharmacodynamics

Pipecuronium Bromide is one of the most potent agents in the aminosteroid class. Onset of maximal neuromuscular block after an intubating dose typically occurs within about 2-3 minutes, which is slower than agents used for rapid-sequence intubation. Clinical duration of action is long (commonly on the order of 80-100 minutes or more after an intubating dose), substantially longer than that of intermediate-acting agents such as vecuronium or rocuronium, and comparable to or longer than pancuronium. Recovery is dose-dependent, and repeat/maintenance doses can produce cumulative prolongation of block.

Pharmacokinetics

Pipecuronium Bromide does not cross the blood-brain barrier or the placenta to a clinically significant extent at usual doses. It undergoes minimal hepatic metabolism and is eliminated predominantly unchanged by the kidneys, with a smaller fraction excreted in bile/feces. Because renal excretion is the major elimination pathway, renal impairment substantially prolongs its duration of action; hepatic impairment can also prolong its effect to a lesser degree.

• Arduan is given only by direct intravenous injection (bolus), by or under the direct supervision of personnel trained and skilled in airway management, tracheal intubation, and mechanical ventilation.
• It must be used only where facilities for immediate tracheal intubation, oxygen administration, and controlled/assisted ventilation are available, and where continuous monitoring of neuromuscular function (e.g., train-of-four peripheral nerve stimulation) and vital signs is possible.
• Arduan must always be administered after the patient is adequately anesthetized/sedated and unconscious - never as a substitute for anesthesia or sedation.
• Before tracheal extubation, adequate spontaneous recovery of neuromuscular function must be confirmed clinically and, where appropriate, reversed pharmacologically with an anticholinesterase agent (e.g., neostigmine) together with an anticholinergic agent (e.g., glycopyrrolate or atropine), and confirmed by train-of-four monitoring.
• Do not mix in the same syringe or administer through the same needle/line as alkaline solutions (e.g., barbiturate solutions), as this may cause precipitation.

Several agents can clinically significantly potentiate or antagonize the neuromuscular blockade produced by Arduan; dosing and monitoring must account for concurrent therapy.

Agents that may potentiate (prolong/intensify) the block

• Volatile inhalational anesthetics (e.g., halothane, isoflurane, enflurane, sevoflurane) - potentiate neuromuscular blockade in a dose- and time-dependent manner.
• Aminoglycoside and certain other antibiotics (e.g., gentamicin, tobramycin, clindamycin, tetracyclines) - impair presynaptic acetylcholine release and can markedly potentiate and prolong block, occasionally causing prolonged apnea.
• Other non-depolarizing neuromuscular blockers - additive or synergistic block.
• Magnesium salts, calcium channel blockers, lithium, quinidine/quinine, local anesthetics - can potentiate neuromuscular blockade.
• Electrolyte disturbances, particularly hypokalemia and hypermagnesemia (e.g., from diuretics or other causes), enhance the degree and duration of block.

Agents that may antagonize (reduce) the block or cause resistance

• Chronic use of anticonvulsants such as phenytoin or carbamazepine has been associated with resistance to non-depolarizing agents and a shorter duration of block.

See Contraindications for hypersensitivity and Precautions and Warnings for the requirement to reverse and confirm recovery of neuromuscular function before extubation.

Because Arduan produces intentional, complete skeletal muscle paralysis as its therapeutic effect, prolonged paralysis/apnea beyond the expected duration is an expected risk rather than an incidental side effect, and is managed as described in Precautions and Overdose. Other reported adverse effects include:

• Residual (incomplete recovery of) neuromuscular blockade after surgery.
• Cardiovascular changes: bradycardia or, less commonly, tachycardia; transient changes in blood pressure (hypotension or hypertension) - generally less pronounced than with older agents of this class.
• Hypersensitivity/anaphylactoid reactions, which may include skin flushing, rash, or, rarely, bronchospasm.
• Injection-site reactions.
• Rarely, muscle weakness persisting into the postoperative period.

Pregnancy: Data on the use of Arduan in human pregnancy are limited. Arduan should be used during pregnancy (including during cesarean delivery) only if clearly needed and if the anesthesia team judges that the potential benefit justifies the potential risk, since it crosses the placenta only minimally at usual doses but neuromuscular blockade in the mother requires the same airway/ventilatory precautions as in any other patient. Use only under direct medical/anesthesiology supervision.

Lactation: There is limited information on the excretion of Arduan into human breast milk. Because it is used as a single- or short-course intraoperative agent under direct medical supervision and is a large, highly ionized quaternary ammonium compound with generally poor oral bioavailability, clinically significant exposure of a breastfed infant is considered unlikely, but a physician should be consulted regarding breastfeeding after anesthesia with Arduan.

• Respiratory paralysis: Arduan causes complete paralysis of skeletal muscle, including the diaphragm and other respiratory muscles. It must be administered only by, or under the direct supervision of, personnel trained in airway management, with facilities for immediate tracheal intubation, oxygen administration, and controlled/assisted ventilation available at all times.
• Must not be given without adequate anesthesia/sedation: Arduan has no effect on consciousness or pain perception. It must never be administered unless the patient is already adequately anesthetized or sedated and unconscious; giving a paralyzing agent to an insufficiently anesthetized patient is a severe patient-safety hazard (awareness with paralysis).
• Renal and hepatic impairment: Because Arduan is substantially eliminated by the kidneys, renal impairment can markedly prolong its duration of action; dose reduction and prolonged monitoring are needed. Hepatic impairment may also prolong its effect.
• Reversal and confirmation of recovery: Neuromuscular blockade should be reversed with an appropriate anticholinesterase reversal agent when clinically indicated, and full spontaneous or reversed recovery of neuromuscular function should be objectively confirmed (e.g., by train-of-four monitoring) before tracheal extubation, to reduce the risk of postoperative residual paralysis and respiratory complications.
• Drug and electrolyte potentiation: Certain antibiotics (e.g., aminoglycosides), inhalational anesthetics, and electrolyte disturbances such as hypokalemia or hypermagnesemia can potentiate and prolong the block (see Interactions).
• Restricted setting of use: Arduan is not for use outside a monitored anesthesia, operating room, or critical-care setting with continuous cardiorespiratory and neuromuscular monitoring.
• Conditions with altered sensitivity: Use with particular caution and adjusted dosing in myasthenia gravis, myasthenic (Eaton-Lambert) syndrome, other neuromuscular diseases, severe electrolyte disturbances, and in patients who are obese, elderly, or severely debilitated.

Overdose of Arduan presents as excessive or prolonged neuromuscular blockade, manifesting as prolonged skeletal muscle paralysis and apnea/respiratory insufficiency beyond the expected duration. This is a medical emergency requiring immediate medical attention.

Management should be provided in a facility equipped for airway management and mechanical ventilation, and includes maintaining a patent airway, providing controlled ventilation and oxygenation until adequate spontaneous respiration returns, and considering pharmacologic reversal with an appropriate anticholinesterase agent (with an anticholinergic) once spontaneous recovery has begun, guided by neuromuscular monitoring. Anyone caring for a patient with suspected overdose should contact emergency services or a poison control center immediately; no specific home treatment is appropriate for this medicine, which is used only in supervised medical settings.

Store the unreconstituted (lyophilized powder) vials of Arduan under refrigeration (2-8°C), protected from light, unless the specific product's labeling states otherwise; do not freeze. Once reconstituted, use the solution promptly, within the timeframe stated in the manufacturer's product information, and discard any unused portion - the reconstituted solution contains no preservative. Keep all vials out of reach of children and store as directed by the dispensing hospital pharmacy.

• Renal impairment: Arduan is eliminated mainly by the kidneys; in patients with renal impairment, duration of action is significantly prolonged. Lower doses, longer dosing intervals, and close neuromuscular monitoring are required.
• Hepatic impairment: Duration of action may also be prolonged; use cautiously with extended monitoring.
• Elderly patients: May show a prolonged duration of action, often related to age-associated decline in renal function; dose individualization and close monitoring are recommended.
• Obese patients: Dosing should be based on ideal (lean) body weight rather than total body weight to avoid relative overdose and prolonged block.
• Pediatric patients: See Pediatric Use.
• Neuromuscular disease: Patients with myasthenia gravis, myasthenic syndrome, or other neuromuscular disorders may show markedly altered (usually increased) sensitivity; use with extreme caution and reduced, carefully titrated doses.

Arduan is used as a single intravenous dose or as intermittent supplemental doses for the duration of a surgical procedure or period of mechanical ventilation requiring muscle relaxation, as determined by the anesthesiologist/intensivist based on the procedure length and the patient's neuromuscular monitoring results. It is not intended for outpatient, self-administered, or open-ended long-term use; each course of therapy is supervised and time-limited to the period the patient requires paralysis under monitored ventilatory support.

Arduan for injection is supplied as a sterile lyophilized powder that must be reconstituted before use, per the specific product's package insert - typically with the diluent recommended by the manufacturer (such as sterile water for injection or 0.9% sodium chloride injection) to achieve the intended concentration. The reconstituted solution should be inspected visually for particulate matter and discoloration before use, and should be used promptly; discard any unused solution, as it contains no antimicrobial preservative. Do not mix with alkaline solutions (e.g., barbiturates) in the same syringe or line, as precipitation may occur. Reconstitution must be performed by trained pharmacy or anesthesia personnel using aseptic technique.

Neuromuscular blocking agents > Non-depolarizing (competitive) agents > Aminosteroid class > Long-acting agents

Pipecuronium Bromide competitively blocks nicotinic acetylcholine receptors at the postsynaptic membrane of the neuromuscular junction, preventing acetylcholine from binding and triggering depolarization of the motor end-plate. This competitive blockade prevents muscle fiber contraction, producing flaccid skeletal muscle paralysis in a dose-dependent manner, beginning with small, rapidly moving muscles (e.g., eyes, face) and progressing to the limbs, trunk, and finally the diaphragm/respiratory muscles; recovery occurs in the reverse order. Because the blockade is competitive, it can be antagonized by increasing synaptic acetylcholine concentration, for example with an acetylcholinesterase inhibitor.

Use of Arduan in children must be supervised by an anesthesiologist experienced in pediatric anesthesia, with age- and weight-based dosing and continuous neuromuscular and cardiorespiratory monitoring, in the same monitored setting required for adults.

Safety and effectiveness in infants younger than 1 year of age have not been well established, and Arduan is generally not recommended in this age group unless the treating specialist judges the benefit clearly outweighs the risk; children may show variable sensitivity and response compared with adults, and doses must be individualized and titrated to effect using peripheral nerve stimulation, not given on a fixed schedule.